Following the biopharma strategy launched by the Belgian government in 2021, a mid-term review was published on 25 October 2023 by the Boston Consulting Group (BGC) at an event attended by Prime Minister Alexander De Croo, Minister of Social Affairs and Public Health Frank Vandenbroucke and Thomas Dermine, Secretary of State for Recovery and Strategic Investments, responsible for Science Policy, as well as the partners involved in implementing the biopharma strategy over the past two years.
Representatives of the Belgian government, academia and the health and biotech industry signed at the initiative of Prime Minister Alexander De Croo a joint charter pledging to further strengthen Belgium's position in biopharma R&D and production. The President of the European Commission, Ursula von der Leyen, was also present.
Today Belgium ranks third in biopharmaceutical exports, totalling €56 billion. The sector employs more than 40,000 people directly and many more indirectly.
Consult the launch of the R&D Biopharma Platform: Belgium, 'Health & Biotech valley' of the future: https://www.premier.be/en/belgium-health-biotech-valley-tomorrow
To attract more international investment in pharma and biotech, a new website was also launched “Health & Biotech Valley”: http://www.healthbiotechvalley.be/
Read more about this on the websites of the sector federations below:
- pharma.be https://pharma.be/fr/medias/actualites/la-health-biotech-valley-belge-aujourdhui-et-demain
- bio.be/essenscia https://www.essenscia.be/fr/la-belgique-en-bonne-voie-pour-devenir-la-health-biotech-valley-de-leurope/
SOURCES: websites: of Prime Minister Alexander De Croo, of the sector federations pharma.be & bio.be/essenscia.